AR and prostate carcinoma: Derived from an androgen-dependent CWR22 mouse xenograft that relapsed during androgen deprivation, the CWR22Rv1 prostate cancer cell line is androgen-insensitive, expresses different AR isoforms4, 8, 9, 27, 62, and is expected to display enhanced ARE recognition.